Shopping Cart
- Remove All
- Your shopping cart is currently empty
INY-03-041 trihydrochloride, a potent and highly selective PROTAC-based pan-AKT degrader, comprises Ipatasertib, an ATP-competitive AKT inhibitor, conjugated to Lenalidomide. It effectively inhibits AKT1, AKT2, and AKT3 with IC50 values of 2.0, 6.8, and 3.5 nM, respectively [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | INY-03-041 trihydrochloride, a potent and highly selective PROTAC-based pan-AKT degrader, comprises Ipatasertib, an ATP-competitive AKT inhibitor, conjugated to Lenalidomide. It effectively inhibits AKT1, AKT2, and AKT3 with IC50 values of 2.0, 6.8, and 3.5 nM, respectively [1]. |
Targets&IC50 | Akt1:2.0 nM, Akt2:6.8 nM, Akt3:3.5 nM |
Molecular Weight | 907.8 |
Formula | C44H59Cl4N7O5 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.